ODS new address
This article was originally published in The Tan Sheet
NIH's Office of Dietary Supplements' move has been completed (1"The Tan Sheet, June 10, 2002, p. 8); the new address is National Institutes of Health, 6100 Executive Blvd., Room 3B01, MSC 7517, Bethesda, Md., 20892...
You may also be interested in...
NIH's Office of Dietary Supplements is moving to a new location due to increased staff size and anticipated continued growth
BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.